Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Jun 30, 2022
  • participants needed
    680
  • sponsor
    Ipsen
Updated on 10 June 2021
Investigator
Ipsen Recruitment Enquiries
Primary Contact
IRCCS Ospedale casa Sollievo Della Sofferenza (0.0 mi away) Contact
+141 other location
carcinoma
vegf
growth factor
cabozantinib
targeted therapy
advanced renal cell carcinoma

Summary

The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

Description

The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx Summary of Product Characteristics (SmPC).

Details
Condition Adenocarcinoma, Malignant neoplasm of kidney, Renal Cell Carcinoma, Kidney Cancer, Malignant Adenoma, Renal Cell Cancer, Renal Cancer, clear cell renal cell carcinoma
Treatment Data Collection
Clinical Study IdentifierNCT03419572
SponsorIpsen
Last Modified on10 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years old
Has a diagnosis of advanced RCC
Has received at least one prior VEGF-targeted therapy
For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
No previous exposure to cabozantinib prior to inclusion
Not concurrently involved in an interventional study
Consents to participate in this noninterventional study

Exclusion Criteria

There are no exclusion criteria for this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note